Combination Of Computational Methods With A Drug Repurposing Strategy Identifies A Compound Targeting Chondrocyte Hypertrophy

Osteoarthritis and Cartilage, vol. 31, pp. S9

Abstract

Purpose: To this date, there is no targeted pharmacological treatment approved for osteoarthritis (OA) by the European Medicines Agency (EMA) or Food and Drug Administration (FDA). Hypertrophic differentiation of articular chondrocytes is observed in the early stages of OA, which leads to the degradation of the cartilage and drives the progression of the disease. Therapies targeting chondrocyte hypertrophy are currently limited as chondrocyte heterogeneity in cartilage poses a significant obstacle in studying signaling pathways governing this phenotypic switch.

Authors 7

1. J. Veldman

   Erasmus MC

   Affiliation as printed

   Erasmus MC, Rotterdam, Netherlands

2. M.N. Ferrao Blanco

   Erasmus MC

   Affiliation as printed

   Erasmus MC, Rotterdam, Netherlands

3. N. Kops

   Erasmus MC

   Affiliation as printed

   Erasmus MC, Rotterdam, Netherlands

4. K. Sivasubramaniyan Aachen Galapagos Nederland

   Erasmus MC · Galapagos (Netherlands)

   Affiliation as printed

   Erasmus MC, Rotterdam, Netherlands

   Galapagos Nederland, Leiden, Netherlands

5. Jeroen van Rooij

   Erasmus MC

   Affiliation as printed

   Erasmus MC, Rotterdam, Netherlands

6. E. Farrell

   Erasmus MC

   Affiliation as printed

   Erasmus MC, Rotterdam, Netherlands

7. G.J. van Osch

   Erasmus MC

   Affiliation as printed

   Erasmus MC, Rotterdam, Netherlands